Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan L Cohn

Showing results (151-160 of 183) with videos related to

Pageof 19
Sort By:
Cancer Research|July 21, 2012
Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastomaKelly R Ostler, Qiwei Yang, Timothy J Looney, et al.
Cancer|June 6, 2022
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual diseaseAmi V Desai, Mark A Applebaum, Theodore G Karrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2011
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology GroupJudith G Villablanca, Wendy B London, Arlene Naranjo, et al.
Cell Reports|May 1, 2024
Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiationMonica Pomaville, Mohansrinivas Chennakesavalu, Pingluan Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with NeuroblastomaMark A Applebaum, Erin K Barr, Jason Karpus, et al.
The Lancet. Oncology|July 30, 2013
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trialSusan G Kreissman, Robert C Seeger, Katherine K Matthay, et al.
JCO Global Oncology|December 23, 2025
Adaptive Clinical Neuroblastoma Risk Groups-Tailoring Treatment in Low- and Middle-Income Countries: An International Neuroblastoma Risk Group ProjectWendy B London, Gabriela Villanueva, Derek Shyr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2017
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning MeetingJulie R Park, Rochelle Bagatell, Susan L Cohn, et al.
Radiology|May 19, 2011
Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group ProjectHervé J Brisse, M Beth McCarville, Claudio Granata, et al.
NPJ Precision Oncology|November 7, 2024
Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathologySiddhi Ramesh, Emma Dyer, Monica Pomaville, et al.
Pageof 19

Showing results (151-160 of 183) with videos related to

Sort By:
Pageof 19
Cancer Research|July 21, 2012
Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastomaKelly R Ostler, Qiwei Yang, Timothy J Looney, et al.
Cancer|June 6, 2022
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual diseaseAmi V Desai, Mark A Applebaum, Theodore G Karrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2011
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology GroupJudith G Villablanca, Wendy B London, Arlene Naranjo, et al.
Cell Reports|May 1, 2024
Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiationMonica Pomaville, Mohansrinivas Chennakesavalu, Pingluan Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with NeuroblastomaMark A Applebaum, Erin K Barr, Jason Karpus, et al.
The Lancet. Oncology|July 30, 2013
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trialSusan G Kreissman, Robert C Seeger, Katherine K Matthay, et al.
JCO Global Oncology|December 23, 2025
Adaptive Clinical Neuroblastoma Risk Groups-Tailoring Treatment in Low- and Middle-Income Countries: An International Neuroblastoma Risk Group ProjectWendy B London, Gabriela Villanueva, Derek Shyr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2017
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning MeetingJulie R Park, Rochelle Bagatell, Susan L Cohn, et al.
Radiology|May 19, 2011
Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group ProjectHervé J Brisse, M Beth McCarville, Claudio Granata, et al.
NPJ Precision Oncology|November 7, 2024
Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathologySiddhi Ramesh, Emma Dyer, Monica Pomaville, et al.
Pageof 19